Telavancin: a novel lipoglycopeptide for serious Gram-positive infections

被引：34

作者：

Laohavaleeson, Somvadee ^{[1
]}

Kuti, Joseph L. ^{[1
]}

Nicolau, David P. ^{[1
]}

机构：

[1] Hartford Hosp, Ctr Antiinfect Res & Dev, Ishikari, Hokkaido 06102, Japan

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2007年 / 16卷 / 03期

关键词：

glycopeptide; Gram-positive infection; lipoglycopeptide; telavancin; TD-6424;

D O I：

10.1517/13543784.16.3.347

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Telavancin, a once-daily dosing lipoglycopeptide derived from vancomycin, has a broad-spectrum microbiologic activity against Gram-positive bacteria, including vancomycin-resistant staphylococci. Telavancin displays a dual mode of action and a rapid bactericidal killing. The in vitro activity of telavancin is superior to vancomycin and comparable with, or greater than, linezolid, daptomycin and other novel lipoglycopeptides. Telavancin is effective against Gram-positive pathogens in animal models of soft tissue infections and deep-seated infections including endocarditis, pneumonia and bacteremia. Clinical experience with telavancin in Phase II and III studies for complicated skin and skin structure infections have demonstrated similar efficacy and tolerability compared with standard anti-staphylococcal beta-lactams and vancomycin. Telavancin is in Phase III studies for nosocomial pneumonia. Telavancin seems to be promising as a novel agent for empiric therapy or as an alternative agent in serious infections caused by clinically important resistant Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus, vancomycin intermediate-susceptible S. aureus, vancomycin-resistant S. aureus and vancomycin-resistant enterococci.

引用

页码：347 / 357

页数：11

共 51 条

[1] Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus [J].

Barcia-Macay, Maritza ;

Lemaire, Sandrine ;

Mingeot-Leclercq, Marie-Paule ;

Tulkens, Paul M. ;

Van Bambeke, Francoise .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (06) :1177-1184

[2]

BARCIAMACAY M, 2005, 45 INT C ANT AG CHEM, pA1831

[3] DIMERIZATION AND MEMBRANE ANCHORS IN EXTRACELLULAR TARGETING OF VANCOMYCIN GROUP ANTIBIOTICS [J].

BEAUREGARD, DA ;

WILLIAMS, DH ;

GWYNN, MN ;

KNOWLES, DJC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (03) :781-785

[4] The antimicrobial armamentarium: Evaluating current and future treatment options [J].

Bosso, JA .

PHARMACOTHERAPY, 2005, 25 (10) :55S-62S

[5]

BRAUERS J, 2006, 16 EUR C CLIN MICR I, P1582

[6] Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects [J].

Burriere, S ;

Genter, F ;

Spencer, E ;

Kitt, M ;

Hoelscher, D ;

Morganroth, J .

JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (07) :689-695

[7] Vancomycin analogues active against vanA-resistant strains inhibit bacterial transglycosylase without binding substrate [J].

Chen, L ;

Walker, D ;

Sun, B ;

Hu, Y ;

Walker, S ;

Kahne, D .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (10) :5658-5663

[8]

COREY R, 2006, 44 INF DIS SOC AM TO

[9] Defining the need for new antimicrobials: clinical and economic implications of resistance in the hospitalised patient [J].

DeRyke, CA ;

Maglio, D ;

Nicolau, DP .

EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (06) :873-889

[10]

DRAGHI DC, 2005, 45 ICAAC WASH DC US, P177

← 1 2 3 4 5 6 →